Atara Biotherapeutics Inc
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as… Read more
Atara Biotherapeutics Inc (ATRA) - Net Assets
Latest net assets as of September 2025: $-36.63 Million USD
Based on the latest financial reports, Atara Biotherapeutics Inc (ATRA) has net assets worth $-36.63 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($30.17 Million) and total liabilities ($66.80 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-36.63 Million |
| % of Total Assets | -121.44% |
| Annual Growth Rate | N/A |
| 5-Year Change | -121.04% |
| 10-Year Change | -130.87% |
| Growth Volatility | 100.92 |
Atara Biotherapeutics Inc - Net Assets Trend (2012–2024)
This chart illustrates how Atara Biotherapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Atara Biotherapeutics Inc (2012–2024)
The table below shows the annual net assets of Atara Biotherapeutics Inc from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-97.28 Million | +1.96% |
| 2023-12-31 | $-99.23 Million | -178.36% |
| 2022-12-31 | $126.64 Million | -54.71% |
| 2021-12-31 | $279.61 Million | -39.52% |
| 2020-12-31 | $462.34 Million | +59.00% |
| 2019-12-31 | $290.78 Million | -14.19% |
| 2018-12-31 | $338.86 Million | +90.51% |
| 2017-12-31 | $177.86 Million | -29.90% |
| 2016-12-31 | $253.74 Million | -19.47% |
| 2015-12-31 | $315.10 Million | +205.38% |
| 2014-12-31 | $103.18 Million | +1036.57% |
| 2013-12-31 | $-11.02 Million | -195.60% |
| 2012-12-31 | $-3.73 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Atara Biotherapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 205044300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | % |
| Other Comprehensive Income | $8.00K | % |
| Other Components | $1.96 Billion | % |
| Total Equity | $-97.28 Million | 100.00% |
Atara Biotherapeutics Inc Competitors by Market Cap
The table below lists competitors of Atara Biotherapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Arzum Elektrikli Ev Aletleri Sanayi ve Ticaret AS
IS:ARZUM
|
$22.14 Million |
|
Moulinvest
PA:ALMOU
|
$22.14 Million |
|
Drb Holding
KO:004840
|
$22.14 Million |
|
Oriental Aromatics Limited
NSE:OAL
|
$22.14 Million |
|
X4 PHARMACEUTIC. DL-001
F:48Q
|
$22.13 Million |
|
Chuwa Wool Industry Co Taiwan Ltd
TW:1439
|
$22.11 Million |
|
TS Corp Preference Shares
KO:001795
|
$22.11 Million |
|
YLAB Corporation
KQ:432430
|
$22.10 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Atara Biotherapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -99,231,000 to -97,283,000, a change of 1,948,000.
- Net loss of 85,403,000 reduced equity.
- New share issuances of 59,951,000 increased equity.
- Other comprehensive income increased equity by 212,000.
- Other factors increased equity by 27,188,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-85.40 Million | -87.79% |
| Share Issuances | $59.95 Million | +61.63% |
| Other Comprehensive Income | $212.00K | +0.22% |
| Other Changes | $27.19 Million | +27.95% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Atara Biotherapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-5.08 | $5.23 | x |
| 2013-12-31 | $-285.17 | $5.23 | x |
| 2014-12-31 | $517.36 | $5.23 | x |
| 2015-12-31 | $307.92 | $5.23 | x |
| 2016-12-31 | $220.78 | $5.23 | x |
| 2017-12-31 | $148.90 | $5.23 | x |
| 2018-12-31 | $193.36 | $5.23 | x |
| 2019-12-31 | $141.68 | $5.23 | x |
| 2020-12-31 | $156.25 | $5.23 | x |
| 2021-12-31 | $74.63 | $5.23 | x |
| 2022-12-31 | $31.04 | $5.23 | x |
| 2023-12-31 | $-23.42 | $5.23 | x |
| 2024-12-31 | $-12.99 | $5.23 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Atara Biotherapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -66.23%
- • Asset Turnover: 1.18x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-52.31%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-122.93 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-86.63 Million |
| 2014 | -27.14% | 0.00% | 0.00x | 1.03x | $-38.32 Million |
| 2015 | -18.16% | 0.00% | 0.00x | 1.03x | $-88.73 Million |
| 2016 | -31.15% | 0.00% | 0.00x | 1.04x | $-104.42 Million |
| 2017 | -67.18% | 0.00% | 0.00x | 1.22x | $-137.28 Million |
| 2018 | -68.08% | 0.00% | 0.00x | 1.16x | $-264.58 Million |
| 2019 | -100.07% | 0.00% | 0.00x | 1.18x | $-320.05 Million |
| 2020 | -66.32% | -8632.32% | 0.01x | 1.27x | $-352.85 Million |
| 2021 | -121.65% | -1672.28% | 0.04x | 1.67x | $-368.10 Million |
| 2022 | -180.28% | -359.12% | 0.17x | 2.97x | $-240.97 Million |
| 2023 | 0.00% | -3220.88% | 0.05x | 0.00x | $-266.20 Million |
| 2024 | 0.00% | -66.23% | 1.18x | 0.00x | $-75.67 Million |
Industry Comparison
This section compares Atara Biotherapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Atara Biotherapeutics Inc (ATRA) | $-36.63 Million | 0.00% | N/A | $22.13 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |